Dr. Boarhead’s Summary of Global Updates on the 2019 Novel Coronavirus: 13 April 2021
1. 《自然》：
将积极监测与有针对性的临床试验相结合，不仅有助于确保当前新冠疫苗的安全性，还能在疫情期间及过后，针对可能实施的强化注射剂量与年度接种指导公共卫生政策。
（ 4 月 1 日）
［关键信息］
将积极监测与有针对性的临床试验相结合，可为疫情后的政策做好准备。
Nature
:
The combination of active surveillance and targeted clinical trials is not just important for assuring the safety of current COVID-19 vaccines. These studies will also inform public-health policies around the safety of booster shots or annual vaccinations that might be needed for the duration of the pandemic and beyond.
<1 Apr.>
[key info]
To combine active surveillance with targeted clinical trials is a preparation for post-pandemic policies.
https://www.nature.com/articles/d41586-021-00880-9
2. bioRxiv：
针对 B.1.427 和 B.1.429 变异株躲避中和抗体的能力，研究人员进行多次实验室试验。结果显示，辉瑞或莫德纳疫苗接种两剂者体内产生的中和抗体，在抵抗这两种变异株时有效性是抵抗其他毒株的三分之一。
（ 4 月 1 日）
［关键信息］
辉瑞和莫德纳疫苗抵御 B.1.427 和 B.1.429 的有效性较低。
bioRxiv:
Laboratory tests of B.1.427 and B.1.429’s ability to elude neutralizing antibodies were conducted. The tests showed that neutralizing antibodies generated by people who had received two doses of either the Pfizer or the Moderna vaccine were, on average, three times less potent against these two variants than against others.
<1 Apr.>
[Key info]
Pfizer and Moderna vaccines are less effective in protecting against B.1.427 and B.1.429 than other variants.
https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1
3. 《柳叶刀》：
癌症患者和健康对照组接种 BNT162b2 疫苗后的副作用相似，只是癌症患者出现肌肉疼痛的频率明显较高。然而，接种疫苗后两组均无免疫相关的肌炎确诊病例。
（ 4 月 1 日）
［关键信息］
BNT162b2 疫苗被证明对感染新冠病毒的癌症患者是安全的。
Lancet
:
The side-effect profile of BNT162b2 injection was similar in the healthy controls and the patients with cancer, apart from muscle pain, which was significantly more common among patients with cancer. However, no immune-related myositis was diagnosed after vaccination in either cancer patients or controls.
<1 Apr.>
[key info]
BNT162b2 vaccine is proved safe for COVID-19 patients with cancer.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00155-8/fulltext
4. 《科学》：
在食蟹猴体内开展的药代动力学研究表明，中和抗体 LY-CoV555 的平均半衰期为 13 天，与标准的人体治疗性抗体一致。在恒河猴攻毒模型中，病毒接种后 6 天采集的样本显示，低至 2.5 mg/kg 的该抗体预防剂量可降低上、下呼吸道的病毒复制。
（ 4 月 5 日）
［关键信息］
LY-CoV555 抗体可助非人灵长类动物抵御新冠。
Science
:
A pharmacokinetic study of the neutralizing antibody LY-CoV555 conducted in cynomolgus monkeys demonstrated a mean half-life of 13 days, consistent with a typical human therapeutic antibody. In a rhesus macaque challenge model, prophylactic doses of the antibody as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tracts in samples collected 6 days following viral inoculation.
<5 Apr.>
[key info]
LY-CoV555 protects against SARS-CoV-2 infection in non-human primates.
https://stm.sciencemag.org/content/early/2021/04/05/scitranslmed.abf1906
5. 《柳叶刀》：
33.62% 的新冠肺炎患者在确诊后 6 个月内查出神经或精神疾病， 12.84% 的患者系首次确诊这些疾病。新冠肺炎患者确诊多数病症的比例高于流感或其他呼吸道感染患者。
（ 4 月 6 日）
Lancet
:
Among patients diagnosed with COVID-19, the incidence of a neurological or psychiatric diagnosis in the following 6 months was 33.62%, with 12.84% receiving their first such diagnosis. Most diagnostic categories were more common in patients who had COVID-19 than in those who had influenza or other respiratory tract infections.
<6 Apr.>
[key info]
COVID-19 may result in neurological or psychiatric diseases.
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(21)00084-5/fulltext
6. 《新英格兰医学杂志》：
B.1.1.7 变异株对于康复患者血清、 BBIBP-CorV 疫苗或 CoronaVac 疫苗接种者血清的中和活性几乎不具有抵抗性，而 B.1.351 相较野生型毒株具有更强抵抗性。经检测，多数疫苗接种者的血清样本失去中和活性。
